Talking Rheumatology Research British Society for Rheumatology

Dr Jason E Liebowitz joins Dr Marwan Bukhari to discuss the metaverse and how the field of rheumatology can utilise virtual and augmented reality to improve the lives of patients.
Listen now to hear about the current technological developments and what this means for future clinical practice! 
You can read this article [https://doi.org/10.1093/rheumatology/kead534] in Rheumatology.
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Professor Doron Rimar joins Dr Cristiana Sieiro Santos to discuss their article, which retrospectively compares the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab.
Listen now to hear the findings and what this means for future clinical practice! 


You can read this article [https://doi.org/10.1093/rheumatology/kead457] in Rheumatology.


Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

What is the leaky pipeline and how do we address it? Prof Christina Duftner (University of Innsbruck) and Prof Isabella Grabner (Vienna University of Economics and Business) join Dr Latika Gupta to discuss the diminishing proportion of women in higher ranking and leadership roles within rheumatology.

Want to read more? Here's your further reading list:
1. Read Christina and Isabella's full paper
2. Read Latika's work on the gender gap in journal Editorial Boards


Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

We're delighted to announce Prof Ernest Choy (University of Cardiff) as the incoming Editor-in-Chief of Rheumatology. In this episode, recorded at ACR23, Ernest tells us about his plans for the journal and the type of research he's keen to see. 

Ernest will take the reins from Dr Marwan Bukhari (Royal Lancaster Infirmary), who finishes his highly productive term as Editor-in-Chief in February 2024.

Want to discuss a potential article? Email editorial@rheumatology.org.uk. 
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

What happens when children and young people with JIA stop biologic therapies for remission? Dr Lianne Kearsley-Fleet and Dr Coziana Ciurtin join Dr Herman Tam to discuss their analysis of the UK JIA Biologics Register.

Lianne is an epidemiologist and lead analyst of the UK JIA Biologics Register, based at the University of Manchester. Coziana is a consultant rheumatologist based at University College London.

Managed by the University of Manchester, the UK JIA Biologics Register is a collaboration between BSR and Versus Arthritis that measures the safety and effectiveness of biologic and biosimilar treatment for juvenile idiopathic arthritis.
 
Want to find out more? Here's your further reading list:
1. Read Lianne and Coziana's full paper
2. Find out more about the UK JIA Biologics Register
3. Explore research from the BSR biologics registers 
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).
Listen now to hear the findings and what this means for future clinical practice! 
You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.


Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.